

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

PODESTA GROUP, INC

2. Address:

1001 G STREET, NW SUITE 900 EAST, WASHINGTON, DC 20001

3. Principal place of business (if different from line 2):

4. Contact Name: KIMBERLEY FRITTS

Telephone: 2023931010

E-mail (optional): LOBBYING@PODESTA.COM

Senate ID #: 31680-2512

House ID #: 31110190

7. Client Name: Self

NOVO NORDISK INC

TYPE OF REPORT

8. Year 2007 Midyear (January 1 - June 30): **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report: => Termination Date: _____ 11. No Lobbying Activity:

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more: => Income (nearest \$20,000): 100,000.00

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more: => Expenses (nearest \$20,000): _____

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- Method A.** Reporting amounts using LDA definitions only
 Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
 Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

S. 1710, Labor-HHS-Education and Related Agencies Appropriations Act, diabetes research funding H. R. 3043, Labor-HHS-Education and Related Agencies Appropriations Act, diabetes research funding S. 1859, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, drug importation/FDA provisions H. R. 3161, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, drug importation/FDA provisions H. R. 2638, Homeland Security Appropriations Act, drug importation provisions S. 1644, Homeland Security Appropriations Act, drug importation provisions H. Con. Res. 99, Budget Resolution, Medicare/Medicaid, drug importation, and comparative effectiveness provisions S. Con. Res. 21, Budget Resolution, Medicare/Medicaid, drug importation, and comparative effectiveness provisions

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
Nat'l Institutes of Health (NIH)
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: COHEN, SHARON
Covered Official Position (if applicable): N/A
Name: GERARD, RANDALL
Covered Official Position (if applicable): N/A
Name: KAUDERS, ANDREW
Covered Official Position (if applicable): SR ADV, SEN. MENENDEZ; ED, HOUSE DEM CAUCUS
Name: MORRA, ELIZABETH
Covered Official Position (if applicable): N/A
Name: NICHOLS, SETH
Covered Official Position (if applicable): N/A
Name: PODESTA, ANTHONY
Covered Official Position (if applicable): N/A
Name: POLAK, ANN MARIE
Covered Official Position (if applicable): LEG CORRESPONDENT FOR CONG. MIKE FERGUSON

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

S. 1145, Patent Reform Act of 2007, entire bill H R. 1908, Patent Reform Act of 2007, entire bill

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: COHEN, SHARON

Covered Official Position (if applicable): N/A

Name: GERARD, RANDALL

Covered Official Position (if applicable): N/A

Name: NICHOLS, SETH

Covered Official Position (if applicable): N/A

Name: PODESTA, ANTHONY

Covered Official Position (if applicable): N/A

Name: POLAK, ANN MARIE

Covered Official Position (if applicable): LEG CORRESPONDENT FOR CONG. MIKE FERGUSON

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: PODESTA GROUP, INC Client Name: NOVO NORDISK INC

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

17. House(s) of Congress and Federal agencies contacted: **None**

18. Name of each individual who acted as a lobbyist in this issue area:

19. Interest of each foreign entity in the specific issues listed on line 16 above: **None**

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MED (one per page)

16. Specific lobbying issues:

S. 1710, Labor-HHS-Education and Related Agencies Appropriations Act, diabetes research funding H. R. 3043, Labor-HHS-Education and Related Agencies Appropriations Act, diabetes research funding

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: COHEN, SHARON

Covered Official Position (if applicable): N/A

Name: MORRA, ELIZABETH

Covered Official Position (if applicable): N/A

Name: NICHOLS, SETH

Covered Official Position (if applicable): N/A

Name: POLAK, ANN MARIE

Covered Official Position (if applicable): LEG CORRESPONDENT FOR CONG. MIKE FERGUSON

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

SCHIP (Senate), Medicare cuts to finance SCHIP expansion H. R. 3162, CHAMP Act, Medicare cuts to finance SCHIP expansion H. R. 3162, CHAMP Act, Medicare cuts to finance SCHIP expansion H. Con. Res. 99, Budget Resolution, Medicare/Medicaid provisions S. Con. Res. 21, Budget Resolution, Medicare/Medicaid provisions S. 3, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisions S. 1376, 340B Program Improvement and Integrity Act of 2007, 340 B drug price expansion H. R. 2606, 340B Program Improvement and Integrity Act of 2007, 340 B drug price expansion Possible DRA technical language H. R. 4, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisions S. 3, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisions

17. House(s) of Congress and Federal agencies contacted:

Centers For Medicare and Medicaid Services (CMS)

Executive Office of the President (EOP)

HOUSE OF REPRESENTATIVES

Health & Human Services, Dept of (HHS)

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: COHEN, SHARON

Covered Official Position (if applicable): N/A

Name: KAUDERS, ANDREW

Covered Official Position (if applicable): SR ADV, SEN. MENENDEZ; ED, HOUSE DEM CAUCUS

Name: NICHOLS, SETH

Covered Official Position (if applicable): N/A

Name: PODESTA, ANTHONY

Covered Official Position (if applicable): N/A

Name: POLAK, ANN MARIE

Covered Official Position (if applicable): LEG CORRESPONDENT FOR CONG. MIKE FERGUSON

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: PHA (one per page)

16. Specific lobbying issues:

H. R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H. R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics H. R. 1561, Enhancing Drug Safety and Innovation Act of 2007, PDUFA, drug safety provisions S. 1082, Prescription Drug User Fee Amendments of 2007, PDUFA, drug safety provisions H. R. 2900, Food and Drug Administration Amendments Act of 2007, PDUFA, drug safety provisions S. 467, FACT Act, clinical trials/drug safety provisions S. 596, Safe Internet Pharmacy Act of 2007, clinical trials/drug safety provisions S. 484, Enhancing Drug Safety and Innovation Act of 2007, clinical trials/drug safety provisions S. 993, Pediatric Research Improvement Act, clinical trials/drug safety provisions S. 1024, Safer DATA Act, clinical trials/drug safety provisions H. Con. Res. 99, Budget Resolution, drug importation, comparative effectiveness provisions S. Con. Res. 21, Budget Resolution, drug importation, comparative effectiveness provisions S. 1745, Commerce, Justice, Science and Related Agencies Appropriations Act, DEA drug importation language H. R. 2638, Homeland Security Appropriations Act, drug importation provisions S. 1644, Homeland Security Appropriations Act, drug importation provisions S. 242, Pharmaceutical Market Access and Drug Safety Act of 2007, drug importation provisions S. 1156, Best Pharmaceuticals for Children Amendments of 2007, pediatric exclusivity provisions in FDARA/PDUFA bill S. 623, Access to Life-Saving Medicine Act, follow-on biologics

17. House(s) of Congress and Federal agencies contacted:

Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BRATHWAITE, PAUL
Covered Official Position (if applicable): EXEC DIR, CONGRESSIONAL BLACK CAUCUS 22 MEM
Name: COHEN, SHARON
Covered Official Position (if applicable): N/A
Name: GERARD, RANDALL
Covered Official Position (if applicable): N/A
Name: KAUDERS, ANDREW
Covered Official Position (if applicable): SR ADV, SEN. MENENDEZ; ED, HOUSE DEM CAUCUS
Name: NICHOLS, SETH
Covered Official Position (if applicable): N/A
Name: PODESTA, ANTHONY
Covered Official Position (if applicable): N/A
Name: POLAK, ANN MARIE
Covered Official Position (if applicable): LEG CORRESPONDENT FOR CONG. MIKE FERGUSON

19. Interest of each foreign entity in the specific issues listed on line 16 above: **None**

Signature: ON FILE Date: Aug 14, 2007

Printed Name and Title: KIMBERLEY FRITTS, CEO -

Information Update Page:

Complete ONLY where registration information has changed.

LOBBYIST UPDATE

23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client

Name: BAKER, TEAL
Name: NICHOLS, SETH
Name: SICILIANO, JEN

ISSUE UPDATE

24. General lobbying issues previously reported that NO LONGER pertain

HCR

AFFILIATED ORGANIZATIONS

25. Add the following organization(s)

26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization

Signature: ON FILE Date: Aug 14, 2007

Printed Name and Title: -